BT3:FRA
Lineage Cell Therapeutics Inc
0,89 €
0,00%
(0,00) 1D
9. lis, 08:01:01 GMT+2 · EUR
search
Svi simboli
| Simbol | Cijena | Promjena | Postotna promjena |
|---|
insights_autoGeneriranje najvažnijih uvida za BT3...
Trž. kap.
251,39 mil.
Prosj. kol.
37,00
Količina
0,00
52-tjed. najviša
1,69 €
52-tjed. najniža
0,78 €
Broj djelatnika
75
Trž. kap.
251,39 mil.
Prosj. kol.
37,00
Količina
0,00
52-tjed. najviša
1,69 €
52-tjed. najniža
0,78 €
Broj djelatnika
75
Vijesti
Iz web-izvora i od partnera za vijesti
hr.bloombergadria.com
·
prije 2 dana
Trump slavi rekorde na Wall Streetu, ali iza burzovne euforije krije se opasna istina
MarketBeat
·
prije 28 minuta
Yesway, Inc.'s (NASDAQ:YSWY) Lock-Up Period To End on October 19th
TipRanks
·
prije 36 minuta
Yuanta Securities Details Under-Subscribed S&P 500-Linked ELB Issue
MarketBeat
·
prije 28 minuta
AMERISAFE (NASDAQ:AMSF) Stock Rating Raised to Hold at Wall Street Zen
Profil
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Wikipedia
Lineage Cell Therapeutics Inc – informacije